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MEMBRANE-PERMEABLE PEPTIDE
CAPABLE OF CALPAIN INHIBITION

ischemic conditions or stroke). This in turn produces an
in?ux of calcium ion (Ca++) into the neurons. The rise of

cellular Ca++ level triggers the activation of calpain I.
Calpain I then goes on to degrade cytoskeletal protein such

CROSS-REFERENCE TO RELATED
APPLICATION

as spectrin, Which is believed to disrupt normal cellular
functions, and eventually leads to cell death.

This application claims priority to provisional application
SUMMARY OF THE INVENTION

60/438,318, ?led Jan. 7, 2003.

The invention is directed to proteins and methods of using
the proteins that inhibit calpains I and II. The method

FIELD OF THE INVENTION

The invention pertains to peptides that are membrane
permeable and effective at protecting neurons against
calpain-mediated cell death. In particular, the peptides of the

includes contacting the cell With an effective amount of the

protein for inhibiting calpains I and II.

invention are similar to domains A and C of calpastatin,
Which is a knoWn inhibitor of calpain I and calpain II.

In one aspect of the invention there is provided a peptide
comprising an amino acid sequence (Leu or Ala)-Q(aa)-(Asp
or Glu)-(Xaa)-(Leu or Met), Where Xaa is any amino acid

However, unlike calpastatin, the peptides of the invention do
not target an active cysteine of calpain.

(SEQ ID NO:2). In a preferred embodiment the peptide has
the amino acid sequence, Leu-Ser-Glu-Ala-Leu (LSEAL).
In a another aspect of the invention there is provided a

BACKGROUND OF THE INVENTION

20

With an amount of a peptide comprising the amino acid
sequence (Leu or Ala)-Q(aa)-(Asp or Glu)-(Xaa)-(Leu or

Calpain is a cytosolic calcium-dependent cysteine pro
tease. It is found in all mammalian tissue and cell types. The

Met), Where Xaa is any amino acid (SEQ ID NO:2).

calpain family of proteases consists of tWo recognized

proteins.

In yet another aspect of the invention there is provided a
25

The ?rst member of the calpain family is calpain I or
u-calpain Which is the high sensitivity form and is activated
by a loW calcium concentration (2-75 uM). Calpain I is

ing contacting a cell With an effective amount of a cell

or Ala)-(Xaa)-Asp or Glu)-(Xaa)-(Leu or Met), Where Xaa
30

m-calpain. It has a ribbon like structure and is the loWer

sensitivity form. It is activated by higher concentrations of
calcium (200-800 uM). Calpain II is the dominant form.
Calpastatin is a knoWn endogenous inhibitor of calpain I
and calpain II. It has four internally repeated domains, each

is any amino acid (SEQ ID NO:2).
The invention also provides a method for protecting cells
from UV irradiation-induced cell death comprising exposing
the cells to an effective amount of a polypeptide having the
amino acid sequence, (Leu or Ala)-(Xaa)-(Asp or Glu)
Q(aa)-(Leu or Met), Where Xaa is any amino acid (SEQ ID

35

of Which independently binds a calpain molecule in its

active, Ca++-bound conformation With high a?inity.
Calpains play an important role in various physiological
processes. These processes include, inter alia, the cleavage
of regulatory proteins such as protein kinase C (PKC) and

method for inhibiting calpain-dependent cell death compris

membrane permeable peptide comprising the sequence (Leu

concentrated in synapses and neuronal cell bodies.

The second member of the calpain family is calpain II or

method for inhibiting calpain comprising contacting a cell

NO:2).
Other objects, features and advantages of this invention
Will become apparent upon reading the folloWing detailed

description and referring to the accompanying draWings.
BRIEF DESCRIPTION OF THE DRAWINGS

40

degradation of cytoskeletal or microtubule-associated pro
A more complete appreciation of the invention and many
of the attendant advantages thereof Will be readily obtained

teins (MAP) such as tau. Research has demonstrated that

calpain inhibitors have improved recovery from the memory
performance de?cits and neuromotor disturbances. Calpain
inhibitors inhibit the release of the l3-AP4 protein. There

as the same become better understood by reference to the
45

folloWing detailed description When considered in connec

tion With the accompanying draWings.

fore, it has been suggested that they have a potential use as

therapeutic agents in AlZheimer’s disease. Calpain inhibitors

FIG. 1 is a graphical illustration of the relationship of dose

have also had a protective effect on hypoxia-damaged kid
neys and have had favorable effects folloWing cardiac dam

response of Leu-Ser-Glu-Ala-Leu (LSEAL) (SEQ ID NO.

age produced by ischemias of the heart (e.g., myocardial

3) With ionomycin (ionomycin toxicity) With respect to cell
50

death.

infarction) or reperfusion. It has also been found that calpain

FIG. 2 is a plot of the relationship of ultraviolet light (UV)

inhibitors have cytotoxic effects on tumor cells. Elevated

55

exposure and cell death betWeen cultured Samples of cor
tical neurons containing no LSEAL and Samples containing
LSEAL.
FIG. 3 is a plot of the relationship of the effect of LSEAL

calpain levels are also implicated in the pathophysiology of

cerebral ischemia, platelet activation, NF-KB activation,
muscular dystrophy, cataract progression and rheumatoid
arthritis. With various pathophysiological processes such as,
in?ammations, muscular dystrophies, cataracts of the eyes,
and injuries to the central nervous system (e.g., trauma).
Calpains reside in the cytosol of cells and are activated by
Ca++ at a physiological pH. Its proteolytic activity appears to
be selective against certain target proteins, such as compo

on tau degradation by calpain I.
DETAILED DESCRIPTION OF THE
INVENTION
60

This invention relates to 5-mer peptides and methods of

using these peptides for inhibiting calpain. In particular, the
peptides comprise the folloWing sequence: (Leu or Ala)

nents of the cytoskeleton and calmodulin-dependent
enzymes.
Excessive excitation by a neurotransmitter glutamate can

lead to death of nerve cells (neurons) and neurodegenera
tion. It is believed that toxic effects of glutamate comes from

overactivation of its target glutamate receptors (e.g., under

Q(aa)-(Asp or Glu)-(Xaa)-(Leu or Met), Where Xaa can be
65

any amino acid (SEQ ID NO. 2).
In one embodiment, Xaa is selected from the group

consisting of Ala, Arg, Ile, Leu, Pro, Phe, Ser, Thr and Tyr.

US 7,385,027 B2
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In another embodiment, the peptides include Leu-Ser-Glu

containing 20 mM Hepes, 0.7 mM Na2HPO4, 137 mM
NaCl, 5 mM KCl, 6 mM glucose at a pH 7.4 (l><HBSS) in

Ala-Leu (SEQ ID NO:3), Leu-Ala-Asp-Ala-Leu (SEQ ID
NO:4), Leu-Phe-Glu-Ala-Leu (SEQ ID NO:5), Leu-Tyr
Asp-Ala-Leu (SEQ ID NO:6), Leu-Leu-Glu-Ala-Leu (SEQ
ID NO:7), Leu-Arg-Asp-Ala-Leu (SEQ ID NO:8), Leu-Tyr
Asp-Ala-Met (SEQ ID NO:9), Leu-Thr-Asp-Ala-Leu (SEQ
ID NOzlO), Ala-Leu-Asp-Ala-Leu (SEQ ID NOzll), Leu
Leu-Asp-Ala-Leu (SEQ ID NO: 12), Pro-Ile-Asp-Ala-Leu
(SEQ ID NOzl3) Leu-Ile-Asp-Glu-Leu (SEQ ID NOzl4),
Ala-Ile-Asp-Ala-Leu (SEQ ID NOzl5), Leu-Ile-Asp-Thr
Leu (SEQ ID NOzl6), Leu-Ala-Asp-Ser-Leu (SEQ ID
NOzl7), and Leu-Ser-Asp-Ser-Leu (SEQ ID NOzl8). All of

the presence of 1 mM CaCl2. The calpain inhibitor IV Was

added to permanently block the active cysteine of calpain I.
CaCl2 Was added to activate the calpain I active site. A single
Well of a Nunc-ImmunoTM microWell plate With a Max

iSorpTM surface Was ?lled With 200 pL of the mixture and
incubated at room temperature for 15 minutes. The plate Was
covered and shaken in an orbital shaker for 30 minutes at 370
C. and at 250 rpm.
The Well Was rinsed three times With a rinse solution

comprising l>< concentration of HBSS and 1 mM CaCl2 to

these amino acid sequences are similar to the binding region

remove excess and/ or non-bound calpain I. To prevent direct

of the endogenous inhibitor calpastatin.
One particular ?ve amino acid peptide comprising Leu
Ser-Glu-Ala-Leu (SEQ ID NO. 3) (hereinafter LSEAL is
particularly preferred for its ability to inhibit calpain activity

binding of the phage to the Sample Well, the Well and a

both in vitro and in situ. It Was found that this peptide is
membrane-permeable and effective at protecting neurons

against calpain-mediated cell death in two different para

20

digms.

The phage (approximately 2><l0ll cells) Were added to the

LSEAL is similar to domains Aand C of calpastatin Which

control Well. The plate Was covered and shaken in the orbital
shaker for 30 minutes at 370 C. and at 250 rpm. The phage

have been extensively studied by others in Which they have

Were then transferred to the Sample Well containing calpain

shoWn that regions of calpastatin that are similar to our

peptides are required for full inhibition of calpains. In
addition, other groups have shoWn that mutations of speci?c

25

amino acids in domains A or C, Which are the equivalent

amino acids in our peptide (SEQ ID NO. 3) of the present

invention, result in reduced calpastatin inhibitory action,
indicating that the sequence is likely optimal for calpain
inhibition. These ?ndings suggest that the peptides of the
invention can mimic the actions of calpastatin.
The LSEAL peptide inhibits calpain activity in vitro
toWards the substrate tau protein. Also, this peptide prevents
calpain-dependent cell death in tWo model systems of loW

second Well (hereinafter a control Well) Were treated With a
blocking agent, a 3% bovine serum albumin (BSA) in
l><HBSS in 1 mM CaCl2. The plate Was then covered and
shaken in the orbital shaker for 30 minutes at 370 C. and at
250 rpm. The control Well and the Sample Well Were then
rinsed three times With the rinse solution.

30

I and the plate Was covered and shaken in the orbital shaker
for 30 minutes at 370 C. and at 250 rpm. After incubation,
the plate Was Washed 50 times With the rinse solution to
remove excess or non-bound phage. The ?nal Wash, i.e., the
50th Wash, Was saved and placed in a microtube.
In accordance With the protocol in the NEB instruction
manual, the Sample Well Was eluted four times With HBSS

and 1 mM ethyleneglycol-bis([3-aminoethylether)-N,N,N',
N'-tetraacetic acid (EGTA), a calcium chelating agent. Each
elution With EGTA Was for a period of 10 to 15 minutes at
35

dose ionomycin treatment as Well as UV-induced cell tox

room temperature and 60 rpm shaking. Each of the four
elutions Were saved. The Well Was then eluted With a

icity. While other synthetic inhibitors are available for

solution containing 0.2 M glycine having a pH of 2.2, and

calpains, this peptide has several advantages.

then With 4M solution of urea. As for the elution With
glycine, this step Was performed for 5 minutes at room

First, all other calpain inhibitors target the active site
cysteine of calpain. This leads to signi?cant speci?city loss

40

as many other proteases have cysteine residues at their
active sites that have been shoWn to be modi?ed by these

other inhibitors. As such, it is extremely unlikely that the
peptides Will react With other proteases. The peptides of the
invention mimics a key portion of the calpastatin molecule

45

required for its endogenous and speci?c inhibitory action to
the calpains.
Second, the peptides of the invention are membrane
permeable Without the need for other modi?cations. The
peptides of the present invention can affect changes inside a
cell, and are likely to produce more speci?c effects due to
calpain, and are more membrane-permeable than all previ
ous calpain inhibitors.
The description beloW sets forth the method used to

identify the peptide(s) using the PhD-l2TM phage display

pL of 1M tris-HCl to raise the pH to 9.1 to prevent killing
of the phage. The glycine and urea elutants Were combined.
Each elutant, including the saved ?nal Wash Was titered to
measure the number of phage remaining in the elutant.
Ampli?ed phage Were then titred to determine their
concentration and the process Was repeated four times using

the ampli?ed phage from the previous round. The phage
from the ?nal screening process Were sequenced to deter
mine a consensus binding sequence. The titre results Were as
50

folloWs:

Round 1 (x103): Final Wash:l00; Elution 1:800; Elution
2:615; Elution 3:411; Elution 4:362; Glycine/Urea com
bination:l00.

Round 2 (x102): Final Wash:2; Elution l:l400; Elution
55

system from NeW England Biolabs (NEB). The protocol for

3:120; Elution 4:38; Glycine/Urea:75.
Round 3 (x103): Final Wash:7; Elution l:l4,l30; Elution
2:5495; Elution 3Il800; Elution 4:l570; Glycine/

determining the number of phages is from the NEB Ph.D
l2TM Kit manual, version 2.5. In this method, the active-site
of calpain I Was irreversibly inactivated or blocked With
Calpain Inhibitor IV, and the peptide(s) Were isolated as

temperature folloWed by a neutraliZation step by adding 150

Urea:3l40.
Round 4 Was not titred.
60

In order to demonstrate the effectiveness of the inhibition

calcium-dependent binding peptides. Therefore, these pep

of calpain by the peptides of this invention, tWo in situ

tides have a calpain I conformation-dependent binding

experiments Were conducted using cultured cortical neurons
from rat brains to shoW that the LSEAL peptide inhibited
cell death. In the ?rst experiment, cell death of the neurons

sequence.

A mixture of 500 pL of Hepes balanced salt solution
(HBSS) (2>< concentration) Was mixed With 475 pL distilled
Water, 20 pL of calpain I, 0.5 pL of calpain inhibitor IV and
5 pL of 200 mM CaCl2. Calpain inhibitor IV Was in a bulfer

65

Was induced by exposing the culture to ionomycin. In the
second experiment, cell death Was induced by exposing the
neurons to 30 and 60 mJ/cm2 of UV light. The exposure to

US 7,385,027 B2
5

6

either ionomycin or UV light caused calpain I to be activated
because of ionomycin-mediated calcium ?ux or through
UV-induced receptors, channels or pore-like structures. Cal

TABLE 1-continued
Percentage

cein acetoxymethyl ester Was used as indicator of live
neuron cells While propidium iodide Was used an indicator
of dead neuron cells.

Average cell
death
(ratioed to 0

Micromolar

In the ?rst experiment, ten Samples Were prepared.

percentages

ionomycin Was added to the cultured neuron cells to activate

(vehicle

Percent

(11 =)

(raW data)

raW data:

Control

calpain I. No LSEAL Was added to these Samples. The

treatment

addition of ionomycin to these Samples caused the percent

only) —

age of dead cells to more than triple to an average of 68%.
Sample 3 Was the same as Sample 2 except that 0.00001
micromolar of LSEAL Was added before the ionomycin Was

lonomycin

19

Sample 1
68

alone —

Sample 2

20

cell death Was 83% of no LSEAL. Sample 5 Was the same

as Sample 4 except that 0.001 micromolar LSEAL Was
added. The percentage of cell death Was 63% of no LSEAL.
Sample 6 Was the same as Sample 5 except that 0.01
micromolar LSEAL Was added. The percentage of cell death
Was 61% of no LSEAL. Sample 7 Was the same as Sample
6 except that 0.1 micromolar LSEAL Was added. The
percentage of cell death Was 57% of no LSEAL. Sample 8
Was the same as Sample 7 except that 1.0 micromolar
LSEAL Was added. The percentage of cell death Was 48% of
no LSEAL. Sample 9 Was the same as Sample 8 except that
10.0 micromolar LSEAL Was added. The percentage of cell

of Samples

Cell death

Sample 1 Was a control Sample and included the cultured
cortical neurons only. A baseline for the average percentage
ofcell death Was determined to be 19%. In Sample 2, 0.4 uM

added. The percentage of dead cells averaged of 106% of no
LSEAL. Sample 4 Was the same as Sample 3 except that
0.0001 micromolar of LSEAL Was added. The percentage of

LSEAL)

Number
Standard Error
of the Mean

25

In the second experiment, cell death of the cultured
cortical neurons Was induced by UV light. Samples 11, 12
and 13 Were control Samples Which did not contain any
LSEAL. Sample 11 shoWs the normal % dead cells With no
exposure to UV light. The percentage of cell death Was 18%.
Sample 14 is the same as Sample 11, except for the addition
of 100 uM LSEAL to the culture. The percentage of cell
death Was reduced from 18% to 14%. Sample 12 Was

exposed to 30 mJ/cm2 of UV light. The percentage of cell
30

death Was 58%. The inclusion of the LSEAL before expo
sure reduced the percentage of cell death to 25%. See

Sample 15. If the exposure is increased to 60 mJ/cm2, the
cell death percentage is 74% for the culture Which does not

contain LSEAL (see Sample 13), and 30% for a culture

containing LSEAL (see Sample 16). The data clearly shoW

death Was 35% of no LSEAL. Sample 10 Was the same as 35 that the peptide of the present invention protects neurons

Sample 9 except that 100 micromolar LSEAL Was added.

from UV-induced, calpain-dependent cell death. The data for
the experiment is set forth beloW in Tables 3 and 4, and is
graphically illustrated in FIG. 2.

The percentage of cell death Was 33% of no LSEAL. It is

clear from this experiment that the peptide of the invention
inhibited calpain I activity. The results are summariZed in
Table 1 beloW and the results are graphically illustrated in

40

TABLE 2

FIG. 1
TABLE 1
45

Percentage
Average cell

Micromolar
0 LSEAL

death
(ratioed to 0

Standard Error

Number
of Samples

Percent

LSEAL)

of the Mean

(n =)

(raW data)

100

4.8

13

106

13.0

13

83

10.7

3

Sample

Live Cells

Dead Cells

Total Cells

% Dead Cells

11
12
13
14
15
16

36
25
17
30
78
56

7
33
42
5
26
25

43
58
59
35
104
81

18
58
74
14
25
30

50

(Sample 2)
.00001
LSEAL

TABLE 3

(Sample 3)
.0001
LSEAL

55

(Sample 4)
.001 LSEAL

63

14.2

4

61

9.4

5

57

5.9

7

48

4.9

4

35

3.3

6

33

8.0

3

0 mJ/cm2

60 mJ/cm2

(Sample 6)
0.1 LSEAL

Samples

30 mJ/cm2

(Sample 5)
0.01 LSEAL

UV Light
Exposure

Live
Cells

Dead
Cells

Total
Cells

% Dead
Cells Std Dev

11 (Control)

36

7

43

18

10

14

30

5

35

14

10

12 (Control)

25

33

58

58

1

15

78

26

104

25

2

13 (Control)

17

42

59

74

17

16

56

25

81

30

6

60

(Sample 7)
1 LSEAL

(Sample 8)
10 LSEAL

(Sample 9)
100 LSEAL

(Sample 10)

65

Another experiment Was conducted to shoW the effect of
the proteins of the present invention on the tau protein. The
tau protein is a microtubule-associated protein (MAP). Tau
is a Well-described calpain I substrate. The addition of 100

uM LSEAL inhibits degradation of the protein. The results
are shoWn in FIG. 3.

US 7,385,027 B2
8

7
While the salient features have been illustrated and

the spirit and scope of the invention, and it is therefore not

described With respect to particular embodiments, it should

desired to limit the invention to the exact details shoWn and
described.

be readily apparent that modi?cations can be made Within

SEQUENCE LISTING

<l60> NUMBER OF SEQ ID NOS :

l8

<2lO> SEQ ID NO 1
<2ll> LENGTH: 5
<2l2> TYPE: PRT
<2l3> ORGANISM:

Homo sapiens

<4 00> SEQUENCE:

1

Leu Ser Glu Ala Leu
1
5

<2ll> LENGTH:

5

<2l3> ORGANISM: Homo sapiens
<220> FEATURE:

<22l> NAME/KEY: MISCiFEATURE
<222> LOCATION: (1) ..(1)
<223> OTHER INFORMATION:
<220> FEATURE:

X is L or A

<22l> NAME/KEY: MISCiFEATURE
<222>

LOCATION:

(2) . . (2)

<223> OTHER INFORMATION:
<220> FEATURE:

X is any amino acid

<22l> NAME/KEY: MISCiFEATURE
<222>

LOCATION:

(3) . . (3)

<223> OTHER INFORMATION: X is D or E
<220> FEATURE:

<22l> NAME/KEY: MISCiFEATURE
<222>

LOCATION:

(4) . . (4)

<223> OTHER INFORMATION:
<220> FEATURE:

X is any amino acid

<22l> NAME/KEY: MISCiFEATURE
<222>

LOCATION:

(5) . . (5)

<223> OTHER INFORMATION:

X is L or M

<400> SEQUENCE: 2
Xaa Xaa Xaa Xaa Xaa
l
5

<2ll> LENGTH:

5

<2l3> ORGANISM: Homo sapiens
<400> SEQUENCE: 3
Leu Ser Glu Ala Leu
1
5

<2ll> LENGTH:

5

<2l3> ORGANISM: Homo sapiens
<400> SEQUENCE: 4

Leu Ala Asp Ala Leu
1

5

<2ll> LENGTH: 5
<2l2> TYPE: PRT

<2l3> ORGANISM: Homo sapiens

US 7,385,027 B2
10
—cont inued
<400> SEQUENCE: 5
Leu Phe Glu Ala Leu
l

<2lO> SEQ ID NO
<2ll> LENGTH: 5
<2l2> TYPE: PRT
<2l3> ORGANISM:

Homo sapiens

<400> SEQUENCE: 6

Leu Tyr Asp Ala Leu
l

<2lO> SEQ ID NO
<2ll> LENGTH: 5
<2l2> TYPE: PRT
<2l3> ORGANISM:

Homo sapiens

<400> SEQUENCE: '7
Leu Leu Glu Ala Leu
l

<2lO> SEQ ID NO
<2ll> LENGTH: 5
<2l2> TYPE: PRT
<2l3> ORGANISM:

Homo sapiens

<400> SEQUENCE: 8

Leu Arg Asp Ala Leu
l

<2lO> SEQ ID NO
<2ll> LENGTH: 5
<2l2> TYPE: PRT
<2l3> ORGANISM:

Homo sapiens

<400> SEQUENCE: 9

Leu Tyr Asp Ala Met
l

<2lO> SEQ ID NO 10
<2ll> LENGTH: 5
<2l2> TYPE: PRT
<2l3> ORGANISM:

Homo sapiens

<400> SEQUENCE: lO
Leu Thr Asp Ala Leu
l

<2lO> SEQ ID NO 11
<2ll> LENGTH: 5
<2l2> TYPE: PRT
<2l3> ORGANISM:

Homo sapiens

<400> SEQUENCE: ll
Ala Leu Asp Ala Leu

<2lO> SEQ ID NO 12
<2ll> LENGTH: 5
<2l2> TYPE: PRT
<2l3> ORGANISM:

<400> SEQUENCE:

Homo sapiens

US 7,385,027 B2
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—cont inued

Leu Leu Asp Ala Leu
l

<2lO> SEQ ID NO 13
<2ll> LENGTH:
<2l2> TYPE:

5

PRT

<2l3> ORGANISM:

Homo sapiens

<400> SEQUENCE: l3
Pro Ile Asp Ala Leu
l

<2lO> SEQ ID NO 14
<2ll> LENGTH:
<2l2> TYPE:

5

PRT

<2l3> ORGANISM:

Homo sapiens

<400> SEQUENCE: l4
Leu Ile Asp Glu Leu
l

<2lO> SEQ ID NO 15
<2ll> LENGTH:
<2l2> TYPE:

5

PRT

<2l3> ORGANISM:

Homo sapiens

<400> SEQUENCE: l5
Ala Ile Asp Ala Leu
l

<2lO> SEQ ID NO 16
<2ll> LENGTH:
<2l2> TYPE:

5

PRT

<2l3> ORGANISM:

Homo sapiens

<400> SEQUENCE: l6
Leu Ile Asp Thr Leu
l

<2lO> SEQ ID NO 17
<2ll> LENGTH:
<2l2> TYPE:

5

PRT

<2l3> ORGANISM:

Homo sapiens

<400> SEQUENCE: l7
Leu Ala Asp Ser Leu
1

<2lO> SEQ ID NO 18
<2ll> LENGTH:
<2l2> TYPE:

5

PRT

<2l3> ORGANISM:

Homo sapiens

<400> SEQUENCE:
Leu Ser Asp Ser Leu
1
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Ile-Asp-Ihr-Leu (SEQ ID NOzl6), Leu-Ala-Asp-Ser-Leu

What is claimed is:
1. An isolated 5-mer peptide selected from the group

(SEQ ID NOzl7), and Leu-Ser-Asp-Ser-Leu (SEQ ID

consisting of Leu-Ser-Glu-Ala-Leu (SEQ ID NO:3), Leu

Ala-Asp-Ala-Leu (SEQ ID NO:4), Leu-Phe-Glu-Ala-Leu
(SEQ ID NO:5), Leu-Tyr-Asp-Ala-Leu (SEQ ID NO:6),
Leu-Leu-Glu-Ala-Leu (SEQ ID NO:7), Leu-Arg-Asp-Ala
Leu (SEQ ID NO:8), Leu-Tyr-Asp-Ala-Met (SEQ ID
NO:9), Leu-Thr-Asp-Ala-Leu (SEQ ID NOzlO), Ala-Leu
Asp-Ala-Leu (SEQ D NO: 11), Leu-Leu-Asp-Ala-Leu (SEQ
ID NOzlZ), Ala-Ile-Asp-Ala-Leu (SEQ ID NO: 15), Leu

NOzl8).
5

2. The peptide of claim 1, Wherein the peptide inhibits
calpain activity towards the substrate tau protein.
3. An isolated peptide consisting of the sequence Leu

Ser-Glu-Ala-Leu (SEQ ID NO:3).

